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Abstract  
 
Objective: New strategies are required to rapidly identify novel 
cytostatic agents before embarking on large randomised trials. This 
study investigates whether a change in rate of rise (slope) of serum 
CA125 from before to after starting a novel agent could be used to 
identify cytostatic agents. Tamoxifen was used to validate this 
hypothesis.  
Methods: Asymptomatic patients with relapsed ovarian cancer who 
had responded to chemotherapy were enrolled and had CA125 
measurements taken every 4 weeks, then more frequently when 
rising. Once levels reached 4 times upper limit of normal or nadir, 
they started continuous tamoxifen 20 mg daily, as well as fortnightly 
CA125 measurements until symptomatic progression.  Due to the 
potentially non-linear relationship of CA125 over time it was felt that 
to enable normal approximations to be utilised a natural logarithmic 
standard transformation [ln(CA125)] was the most suitable to 
improve linearity above the common logarithmic transformation to 
base 10. 
Results: From 235 recruited patients, 81 started tamoxifen and had 
at least 4 CA125 measurements taken before and 4 CA125 
measurements taken after starting tamoxifen, respectively.   The 
Manuscript (All Manuscript Text Pages in MS Word format, including References and Figure Legends)
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mean regression slopes from using at least 4 In(CA125) 
measurements immediately before and after starting tamoxifen were 
0·0149 and 0·0093 [ln(CA125)/day] respectively. This difference is 
statistically significant, P = 0·001. Therefore in a future trial with a 
novel agent, at least as effective as tamoxifen, using this effect size, 
the number of evaluable patients needed, at significance level of 5% 
and power of 80%, is 56. 
Conclusions:  Further validation of this methodology is required but 
there is potential to use comparison of mean regression slopes of 
ln(CA125) as an interim analysis measure of efficacy for novel 
cytostatic agents in relapsed ovarian cancer.  
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Introduction  
The activity of cytotoxic chemotherapy is conventionally assessed by 
clinical and radiological measurement of change in size of tumour 
masses. Internationally standardised radiological criteria (RECIST) 
are used to assess response1.  However, many new agents with 
potential anti-cancer activity are predicted to be cytostatic rather 
than cytotoxic.  These approaches may lead to stabilisation of tumour 
growth rather than a rapid shrinkage. The danger of using 
radiological response criteria to assess the clinical utility of these 
agents is that active agents are not always detected in phase II 
clinical trials. For example in patients with advanced gastrointestinal 
stromal tumour (GIST), responses are not always accompanied by 
reductions in tumour size2.  New approaches are therefore required 
to assess the activity of cytostatic agents in phase II clinical trials to 
minimize the chance of active cytostatic agents being discarded.  One 
way to prove a drug has cytostatic activity would be to show that 
tumour growth in individual patients was slower after starting on a 
novel agent than before. In most types of cancer there is not a 
reasonable time frame where it is acceptable to observe tumour 
growth without offering therapy. However, in ovary cancer, most 
patients have rising levels of the serum tumour marker, CA125, for a 
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period whilst remaining asymptomatic.  There is an average lead-
time of four months between the initial rise of the CA125 and 
symptomatic relapse of ovarian cancer, generally requiring 
treatment.  It has been shown that it is preferable to delay 
chemotherapy treatment in such relapsing patients until they 
develop symptoms3.   We postulated that this would be a potential 
group of patients in whom the rate of change of CA125 levels, before 
and after initiation of a novel drug could be an alternative method of 
identifying activity worthy of trial continuation.  
The first stage of this project was to determine whether the rate of 
rise of CA125 is consistent enough to allow comparison of (rate of 
rise) slopes before and after the introduction of a treatment. This 
required sufficient CA125 measurements from patients on no 
therapy or placebo.  A pilot study ascertained that most patients with 
relapsed ovarian cancer would not accept intense CA125 
measurements, if there were no prospect of some therapy once the 
CA125 levels started rising. Although such asymptomatic patients 
with rising serum CA125 levels remain anxious about recommencing 
treatment, many accept a less toxic therapy provided they know that 
they will be closely monitored and able to start cytotoxic treatment 
again as soon as they become symptomatic. 
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Tamoxifen has been shown to have activity in approximately 15% of 
patients with relapsed ovarian cancer4 and is an ideal agent with 
minimal toxicity.  The tolerability of tamoxifen and it’s modest 
activity in ovarian cancer patients (akin to placebo in most), would 
allow us to determine any variability in rate of rise of CA125, as well 
as the chance of detecting some change in the 15% of patients where 
it is active.  Figure 1 shows graphically an outline of what was 
expected to occur with respect to the CA125 measured over time for 
such patients and a range of potential outcomes after the patients 
start taking tamoxifen. 
 
Methods  
We prospectively registered women between May 2005 and 
November 2009 with histologically confirmed recurrent epithelial 
ovarian, fallopian tube or primary peritoneal cancer who had 
completed and responded to treatment for first relapse (i.e second 
course of chemotherapy, NOT after primary adjuvant / neoadjuvant 
therapy), with a fall in their CA125 of at least 50% by the end of 
treatment. A protocol amendment in April 2009 allowed the 
registration of patients who had responded to 2nd, 3rd and 4th line 
relapse therapy as long as their CA125 had fallen by 50% by the end 
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of treatment. No measurable disease was required for trial 
registration.  Patients were ECOG performance status 0-2 and had no 
symptoms of ovarian cancer requiring chemotherapy.  None of the 
patients were taking any hormone therapy and all other concomitant 
medications were at a stable dose throughout the trial period. 
Adequate end organ function was required in all patients including:  
Hb >10g/dl, WCC > 2.5 x 109/l, plts >100 x 109/l, creatinine, AST and 
or ALT < 2 x upper limit of normal, and bilirubin < 1.5x upper limit 
normal.   
  
For each registered patient a baseline or nadir CA125 was 
documented, defined as the lowest CA125 estimate, obtained at least 
3 weeks after completing chemotherapy for relapse.  Once registered, 
patients had serum CA125 concentrations measured monthly, with 
all serial assays of an individual being performed in the same 
laboratory. If a patient’s CA125 level started rising, the frequency of 
the CA125 levels was increased to fortnightly.  When (if) the CA125 
level reached four times the upper limit of normal or the patient’s 
registered lowest nadir level (if higher than normal), the patient was 
contacted, imaging of thorax, abdomen and pelvis was performed and 
they were started on tamoxifen, 20mg daily.  Provided these patients 
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remained stable and asymptomatic whilst taking tamoxifen, CA125 
measurements were continued fortnightly.  
 
CT scans were performed every three months in accordance with 
local practice but responses by RECIST criteria were not expected in 
this study.  Radiological assessment was predominantly for safety 
purposes in the unlikely event that women have significantly 
progressive disease without a rise in CA 125.  Similarly, if at any 
point, a registered patient became symptomatic from their ovarian 
cancer, tamoxifen and study related CA125 measurements were 
stopped, they were withdrawn from the study and treated in 
accordance with local practice.  Asymptomatic patients with a rising 
CA125 level whilst taking tamoxifen were allowed to continue on 
study until they became symptomatic.  
 
The ethics committee approved the protocol and the study was 
conducted in accordance with the Principles of Good Clinical Practice 
and the Declaration of Helskini.  All patients provided written 
informed consent. 
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Statistical Methods 
CA125 values are not naturally normally distributed so a log 
transformation was used to enable linear associations to be 
examined.  Linear regression lines were fitted to each patients data to 
assess any increase or decrease in ln(CA125) levels over the study 
duration, before and after treatment. It was agreed that at least 4 
CA125 measurements were required to fit these linear regression 
lines and statistically assess the potential rise/fall of a patient’s 
CA125 levels before and after treatment with tamoxifen.   All patients 
were included until clinical progression to maximise evaluability and 
sample size.  
 
The percentage of patients with a log linear rise was calculated to 
ensure that sufficient numbers existed to be able to examine the 
association of log linear rise before and after starting tamoxifen.  The 
consistency of the log linear slopes was then examined to determine 
whether comparison before and after introduction of tamoxifen was 
possible.  The individual slopes obtained were then compared using a 
paired t-test. 
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It could be argued that examining the change in slopes of CA125 
levels over time, before and after starting tamoxifen could be 
misleading due to the possibility of regression to the mean. We 
therefore also examined the ln(CA125) slopes of other registered 
patients who were on trial and had four CA125 measurements before 
starting or without starting tamoxifen – usually because they became 
too symptomatic requiring immediate chemotherapy - to act as a 
comparator  group.  
 
Finally the number of patients required to detect a difference in 
ln(CA125) slopes, before and after starting tamoxifen, was calculated. 
This was to determine whether using a comparison of ln(CA125) 
slopes before and after introduction of a novel agent might allow 
more rapid decisions concerning the efficacy of these drugs, 
particularly if they are not expected to show actual tumour shrinkage 
measurable by RECIST.   
 
Results  
235 women were recruited to the study and provided at least one 
trial CA125 sample.  204 patients were recruited after their first 
relapse therapy.  The mean (SD) age in years at the time of 
consenting for study registration was 64.4 (11.0).  
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Fifty-three percent of the study group received tamoxifen (125/235), 
but of these only 81 patients had at least four CA125 measurements 
collected before and after the introduction of tamoxifen. The 
remaining 44 patients had fewer than four CA125 measurements, 
either before or after, or both and were excluded from log linear 
slope analysis.    
 
110 patients (47%) in the study never started tamoxifen, because 
they required chemotherapy treatment for their symptomatic 
ovarian cancer before this.  Only 74 of these patients had at least four 
CA125 measurements before coming off study, 36 patients had fewer 
than four CA125 measurements prior to requiring chemotherapy and 
coming off study. 
 
The mean (SD) baseline (nadir) CA125 value for the 81 patients who 
had at least four CA125 measurements before and after starting 
tamoxifen was 61.5 (106.4).  Table 1 shows the average slope over 
time for the 81 evaluable patients before and after receiving 
tamoxifen.  Figure 2 illustrates graphically CA125 plotted over time 
for these 81 patients. 
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The mean slopes before and after treatment both significantly 
increased over time in this group.  A paired t-test revealed that there 
was a significant difference in the rates of rise across patients over 
time before and after treatment (Table 2), indicating that taking 
tamoxifen slowed the rise in CA125 levels.  Figure 3 represents this 
graphically in a scatter plot. 
 
 
14 percent (11/81) of the patient group who received tamoxifen  
showed a registered decline in their CA125 levels after treatment 
with tamoxifen.   4 patients had a 50% decrease in their CA125 after 
starting tamoxifen, confirmed and maintained for at least 28 days or 
more, thus fulfilling the GCIG criteria of CA125 response5. 
 
CA125 variation and regression to the mean 
In order to explore the effect of regression to the mean in individual 
patients, possibly accounting for the slowing of the rise of CA125 
after starting tamoxifen, we examined the CA125 levels in patients 
who did not start tamoxifen at all.   These patients are likely to have 
had faster growing tumours than those asymptomatic and able to 
start tamoxifen.  If regression to the mean was a significant factor, it 
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would occur in all groups of patients where CA125 is measured over 
time.  The similarity of the mean slope of 0.0131 for the non 
tamoxifen treated group versus 0.0149 in the patients before starting 
tamoxifen suggests that regression to the mean is not having an 
impact.   It is reassuring to note that the mean change in rise in slope 
(Table 3) of 0.0056 in those treated with tamoxifen is significantly 
different. 
 
 
Seventy-four patients had at least 4 CA125 measurements and Table 
3 shows the mean slope derived from fitting a regression line to each 
patient’s measurements after recruitment.  Comparing the mean 
slopes between this group and the pre-tamoxifen group showed a 
non-significant difference between them. 
 
Sample size for future trials 
Using the mean change in slope for tamoxifen described above, the 
number of evaluable patients required to detect an effect of a similar 
size with a novel agent is 74 and 56 with a power of 90% and 80%, 
respectively. However, only 81 out of 235 (34%) patients were 
statistically evaluable therefore 218 and 165 patients respectively 
would have to be registered and start monthly CA125 measurements.    
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Although there may be an issue with bias due to the reduced number 
of evaluable patients in this analysis, attempting to ascertain a 
patient's CA125 slope based on only 2 observations pre-treatment 
would not be a statistically robust approach and could be potentially 
misleading in terms of any assumed linear relationship, the design 
range of evaluable values per patient were explored and made no 
difference to the results per se. Using four observations before and 
four observations after treatment were thought adequate to establish 
any log linear relationship.  Using alternative more complex methods 
led to identical conclusions on a subset of these patients6. 
 
Discussion  
Raw CA125 measurements are not normally distributed; however, 
this study has shown that log transforming the CA125 levels, results 
in data enabling traditional linear regression methods to be used.  We 
have shown that patients have log linear rises in CA125 levels after 
treatment for relapsed ovarian cancer and that these log linear rises 
are consistent enough for comparison before and after therapy. In 
this group of 81 tamoxifen treated patients, there is a significant 
difference (P = 0.001) in the mean of the slopes of the ln(CA125) in 
patients before and after treatment with tamoxifen.  The fact that a 
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significance level of P<0.001 was reached with a reduced sample of 
81 does not in any way jeopardise the power of this design, 
potentially precision may have been improved with an increased 
evaluability rate.  The proportion of patients with a decreasing slope 
(14%) after treatment with tamoxifen is the same as published data 
which suggests that between 13 and 17% patients have a RECIST 
response when treated with tamoxifen7, 8.   
 
The description of the rise/fall of ln(CA125) over time in response to 
the introduction of tamoxifen suggests that this approach would be 
feasible in assessing the activity of novel agents.   However, the 
nature of this “before and after” design of study, without the use of a 
separate control group, in attempting to quantify the true variability 
of patients is not without pitfalls due to potential regression to the 
mean9. We have attempted to examine this by comparing the 
ln(CA125) slopes of patients in the group who did NOT receive 
tamoxifen with the “before” ln(CA125) slope of those in the treated 
group.  The hypothesis is that if regression to the mean is a 
significant factor, you would expect to see variability and different 
slopes in both the untreated group and the pre-treatment group.  As 
we have shown that there is no significant difference in the mean of 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Using CA125 to assess cytostatic agents in ovary cancer 
 15 
these slopes, it is unlikely that the real change observed in the 81 
patients before and after the start of tamoxifen was due to regression 
to the mean.  
 
The results of this study have enabled us to calculate the number of 
patients that may be required to detect a significant difference in 
ln(CA125) slopes to potentially assess other novel agents in the same 
way.  74 and 56 evaluable patients are required for 90 and 80% 
power respectively, this would require recruitment of 218 or 165 
patients and is very similar to the numbers required to assess novel 
agents using well described randomized phase II trial methods using 
RECIST criteria.  However, these methods have been developed to 
assess cytotoxic agents where tumour shrinkage is readily apparent.  
By contrast, this method may be useful, with drugs that are likely to 
be cytostatic and where actual RECIST responses are not expected. 
Currently the only way to ascertain whether a novel agent is active in 
controlling tumor growth (cytostatic) in man is to do an initial 
randomized phase 2 trial with progression free survival as the 
primary endpoint. These trials require the trial drug to be given to far 
more than 56 patients to give a go / no go decision as to whether 
further development is justified. 
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To demonstrate how this approach could also be used in the initial 
selection of potentially toxic cytostatic drugs, application of the 
change in slope ln(CA125) methodology was theoretically applied to 
the randomised tamoxifen versus thalidomide trial recently 
reported10.  In this trial, a target recruitment of 260 ovarian cancer 
patients was planned to provide a 90% chance of proving 
thalidomide active, however at the first interim analysis, 4.5 years 
after trial activation, the study was halted because the PFS and OS 
rates were 38% and 39% higher respectively in the tamoxifen arm. 
Using the change in ln(CA125) slope methodology, a single arm study 
of thalidomide, recruiting 100 patients and treating only half of these 
for 8-12 weeks would have saved a significant number of patients 
exposure to the toxicities of thalidomide to prove that it was inactive. 
To further reduce exposure to potentially toxic, ineffective drugs, it 
might be useful to explore using a doubling rather than a quadrupling 
of nadir CA125 and to include patients with persistently rising levels 
within the upper limit of normal11. 
 
An additional application of this methodology may be in assessment 
of slow release agents such as pegylated liposomal doxorubicin, 
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which may result in an initial rise in CA125 (reflecting initial disease 
progression) because of the slow release nature of therapy, prior to 
‘response’ 12.  Utilising changes in ln(CA125) slopes, asymptomatic 
patients on these agents could continue on the study agent, provided 
that there is a reduction in the rate of rise of CA125, despite it not 
reaching “response” by standard GCIG CA125 criteria.  Disadvantages 
of this methodology, aside from the disappointingly high number of 
registered patients required for an evaluable subset, include the 
possibility that drugs altering CA125 shedding might result in 
spurious results. In vitro studies will be required to exclude this 
possibility. 
 
Although there is a significant difference (P = 0.001) in the mean of 
the slopes of the ln(CA125) in patients before and after treatment 
with tamoxifen, this appears to occur early after starting tamoxifen, 
and in most patients it is short-lived; the number of patients where 
the CA125 response was maintained was only 15%, identical to that 
described in the general literature4.  So this method might also 
paradoxically alert one to drugs that only have a fleeting impact on 
ovarian cancer.   It is thus important to use this method alongside 
standard assessments of response and progression free survival. 
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Retrospective validation of this method has not been possible as 
there are no large data sets where CA125 measurements were 
performed every two weeks for a reasonable period prior to starting 
a trial drug, as in standard practice CA125 is generally measured 2-3 
monthly.  However this work has shown proof of concept that 
utilizing the change in rate of rise of CA125 can be an early indicator 
of activity of new agents, particularly at an interim analysis, where a 
decision may be required as to whether to continue or stop early 
phase studies in the absence of objective RECIST responses.  
Prospective validation will require that agents shown to be active by 
changing the CA125 doubling rate are also shown to prolong PFS / 
OS and agents that fail to decrease the CA125 doubling rate also fail 
to prolong PFS.  
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Table 1:  
Regression slopes for ln(CA125) before and after starting tamoxifen (n=81) 
[ln(CA125)/day] 
 
 Mean  Standard 
deviation 
95% 
Confidence 
interval 
P-value 
Before 0.0149 0.0108 0.0125 – 
0.0173 
<0.0001 
After 0.0093 0.0093 0.0073 – 
0.0114 
<0.0001 
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Table 2: 
Paired slope comparison before and after starting tamoxifen  
[ln(CA125)/day] 
 
Number of 
patients 
Mean change Standard 
deviation 
95% 
Confidence 
interval 
P-value 
81 0.0056 0.0146 0.0024 – 
0.0088 
<0.001 
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Table 3: 
Regression slope for those patients who did not start on tamoxifen 
[ln(CA125)/day] 
 
Number of 
patients 
Mean  Standard 
deviation 
95% 
Confidence 
interval 
P-value 
74 0.0131 0.0132 0.0100 – 
0.0161 
<0.0001 
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Figure 2:  Spaghetti plot of observed ln(CA125) over time for 
each patient  (vertical lines represent start of tamoxifen 
therapy) 
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Figure 3: Scatter plot showing each patient’s slope of 
ln(CA125) before and after treatment with tamoxifen 
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